Despite CETP Loss, Lilly Says Long-Term Strategy Is Starting To Bear Fruit

Drugs like baricitinib for rheumatoid arthritis, abemaciclib for breast cancer and solezumab for Alzheimer’s disease are among the six new molecular entities Lilly could file with regulators in the next 18 months.